| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 16,116 | 12,776* | 13,074 | 12,083 |
| Cost of sales | 3,691 | 2,930* | 3,147 | 3,214 |
| Gross profit | 12,425 | 9,846* | 9,927 | 8,869 |
| Research and development | 5,178 | 4,112* | 4,445 | 4,160 |
| Sales and marketing | 10,297 | 8,808* | 9,610 | 7,869 |
| General and administrative | 6,226 | 4,195* | 4,907 | 3,342 |
| Total operating expenses | 21,701 | 17,114* | 18,962 | 15,371 |
| Loss from operations | -9,276 | -7,268* | -9,035 | -6,502 |
| Interest expense | 311 | 316* | 380 | 363 |
| Interest income | 891 | 764* | 954 | 336 |
| Change in fair value of warrant liabilities | NaN | -125* | 65 | 237 |
| Total other income (expense), net | 580 | 573* | 509 | -264 |
| Net loss | -8,696 | -6,696* | -8,526 | -6,766 |
| Deemed dividend to preferred stockholders | NaN | 584* | 0 | 0 |
| Net loss attributable to common stockholders | -8,696 | -7,280 | -8,526 | -6,766 |
| Basic EPS | -0.32 | -0.512 | -0.4 | -1.47 |
| Diluted EPS | -0.32 | -0.512 | -0.4 | -1.47 |
| Basic Average Shares | 26,835,841 | 14,221,991* | 21,081,330 | 4,589,717 |
| Diluted Average Shares | 26,835,841 | 14,221,991* | 21,081,330 | 4,589,717 |
CARLSMED, INC. (CARL)
CARLSMED, INC. (CARL)